within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CA05_Carindacillin;
model Carindacillin 
   extends Pharmacolibrary.Drugs.ATC.J.J01CA05;

  annotation(Documentation(
    info ="<html><body><p>Carindacillin is an orally active prodrug of the semi-synthetic penicillin carbenicillin. It was used mainly for the treatment of urinary tract infections caused by susceptible bacteria. Carindacillin has been withdrawn from the US market and is not in current clinical use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a single oral dose in healthy adult subjects, based on information that carindacillin is rapidly hydrolyzed to carbenicillin after absorption.</p><h4>References</h4><ol><li><p>Li, YH, et al., &amp; Itoh, T (1999). Mechanism of intestinal absorption of an orally active beta-lactam prodrug: uptake and transport of carindacillin in Caco-2 cells. <i>The Journal of pharmacology and experimental therapeutics</i> 290(3) 958–964. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10454465/&quot;>https://pubmed.ncbi.nlm.nih.gov/10454465</a></p></li><li><p>Naumann, P, &amp; Rosin, H (1973). [Oral carbenicillin treatment with carindacillin (author&#x27;s transl)]. <i>Deutsche medizinische Wochenschrift (1946)</i> 98(46) 2200–None. DOI:<a href=&quot;https://doi.org/10.1055/s-0028-1107223&quot;>10.1055/s-0028-1107223</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/4202153/&quot;>https://pubmed.ncbi.nlm.nih.gov/4202153</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Carindacillin;
